NCT04094311 2026-02-17
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
Clinical Trials
11 trialsPrecursor Cell Lymphoblastic Leukemia-Lymphoma × tisagenlecleucel × Other hematologic neoplasm × Clear all
NCT06408194 2026-02-10
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Stanford University
Phase 1 Recruiting
NCT03642626 2026-01-23
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Masonic Cancer Center, University of Minnesota
Phase 2 Active not recruiting
NCT03601442 2025-12-05
CTL019 Out of Specification MAP for ALL or DLBCL Patients
Novartis
Available
NCT05541341 2025-06-06
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies
Novartis
Recruiting
NCT02435849 2024-02-13
ELIANA
Novartis
Phase 2 Completed
NCT05349201 2022-07-01
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)
Novartis
Completed
NCT02529813 2022-06-30
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03123939 2021-07-21
Phase III B in Acute Lymphoblastic Leukemia
Novartis
Phase 3 Completed
NCT02228096 2020-11-23
ENSIGN
Novartis
Phase 2 Completed
NCT03628053 2020-07-09
OBERON
Novartis
Phase 3 Withdrawn